Overview

Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets

Status:
RECRUITING
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
1. To evaluate the pharmacokinetics of Hemay005 tablets on midazolam and its active metabolite -hydroxymidazolam after multiple administration; 2. Evaluate the effect of Hemay005 tablet on QT interval; 3. To investigate the effect of Hemay 005 tablets on inflammatory factors.
Phase:
PHASE1
Details
Lead Sponsor:
Ganzhou Hemay Pharmaceutical Co., Ltd
Treatments:
Hemay005
Midazolam